Luke Evnin Sells 108,606 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 108,606 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66. Following the sale, the director owned 2,550,674 shares in the company, valued at approximately $1,555,911.14. The trade was a 4.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total transaction of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $40,921.83.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total value of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total value of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total value of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total value of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total value of $39,330.24.

Werewolf Therapeutics Trading Down 1.6%

HOWL stock opened at $0.61 on Wednesday. Werewolf Therapeutics, Inc. has a 1-year low of $0.56 and a 1-year high of $2.38. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. The company has a market capitalization of $29.67 million, a price-to-earnings ratio of -0.38 and a beta of 0.74. The business has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.28.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several large investors have recently added to or reduced their stakes in HOWL. MPM Asset Management LLC lifted its stake in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. MPM Bioimpact LLC raised its holdings in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after buying an additional 20,799 shares during the period. Bank of America Corp DE lifted its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the last quarter. Vanguard Group Inc. boosted its stake in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after buying an additional 109,796 shares during the period. Finally, Jane Street Group LLC bought a new position in Werewolf Therapeutics during the second quarter valued at $409,000. 64.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on HOWL shares. Wedbush downgraded shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Friday, December 19th. Bank of America dropped their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. HC Wainwright cut their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 19th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Citizens Jmp downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.